XML 57 R22.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Other Consolidated Financial Statement Detail | 6 Months Ended
--- | ---
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Other Consolidated Financial Statement Detail | Other Consolidated Financial Statement Detail Other Income (Expense), Net Components of other income (expense), net, are summarized as follows:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2017 |  | 2016 |  | 2017 |  | 2016
Interest income | $ | 16.9 |  |  | $ | 15.4 |  |  | $ | 33.6 |  |  | $ | 26.6 |
Interest expense | (63.6 | ) |  | (65.9 | ) |  | (127.0 | ) |  | (129.2 | )
Gain (loss) on investments, net | (13.4 | ) |  | (2.7 | ) |  | (11.0 | ) |  | (1.1 | )
Foreign exchange gains (losses), net | (2.3 | ) |  | 0.2 |  |  | 1.7 |  |  | 2.3 |
Other, net | (5.8 | ) |  | (5.5 | ) |  | (3.1 | ) |  | (9.9 | )
Total other income (expense), net | $ | (68.2 | ) |  | $ | (58.5 | ) |  | $ | (105.8 | ) |  | $ | (111.3 | )
Other Current Assets Other current assets include prepaid taxes totaling approximately $881.4 million and $817.0 million as of June 30, 2017 and December 31, 2016, respectively. Accrued Expenses and Other Accrued expenses and other consists of the following:
(In millions) | As of June 30, 2017 |  | As of December 31, 2016
Current portion of contingent consideration obligations and milestones | $ | 580.7 |  |  | $ | 580.8 |
Revenue-related reserves for discounts and allowances | 533.3 |  |  | 438.6 |
Royalties and licensing fees | 195.8 |  |  | 195.8 |
Collaboration expenses | 188.0 |  |  | 130.9 |
Employee compensation and benefits | 186.6 |  |  | 282.9 |
Construction in progress | 161.3 |  |  | 134.0 |
Accrued TECFIDERA litigation settlement and license charges | — |  |  | 454.8 |
Other | 591.2 |  |  | 685.7 |
Total accrued expenses and other | $ | 2,436.9 |  |  | $ | 2,903.5 |
Pricing of TYSABRI in Italy - AIFA In the first quarter of 2017, we reached an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods. As a result, in the first quarter of 2017 we recognized EUR 41.8 million (approximately $45.0 million) in revenues for sales which were previously deferred. These amounts were previously accrued for and included in the table above in Other. For additional information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 20, Litigation, to our consolidated financial statements included in our 2016 Form 10-K.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration